Solvay Pharmaceuticals
CompanyBelgium
Solvay Pharmaceuticals develops 4 assets, the furthest approved (dydrogesterone). Mostly small molecule acting on lipid and ceramide metabolism, PPARA and PGR; based in Belgium.
- Assets
- 4
- Furthest
- Approved
- Trials
- 23
- Signals
- 1
Pipeline
4Progestogen receptor agonist used in hormone replacement therapy
ApprovedSmall moleculePGRmenopause (Phase 3)recurrent miscarriage (Phase 3)
PPAR alpha agonist regulating lipid metabolism
ApprovedSmall moleculeLipid and ceramide metabolismPPARAdyslipidemiahypercholesterolemia
HMG-CoA reductase inhibitor and PPAR-alpha agonist combination regulating lipid metabolism.
ApprovedSmall moleculeLipid and ceramide metabolismPPARAcerebrovascular diseasecoronary heart disease
1 more asset
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms8
- Trials35
- Signals1
- Similar companies6
Updated 7 Oct 2026 · 178 sources